763SIP8/MPLA-5 vaccine
Alternative Names: 763SIP8/MPLA-5; Recombinant HIV-1 envelope protein SOSIP v8.2 763 vaccine; SOSIP v8.2 763 + MPLA vaccineLatest Information Update: 22 Sep 2023
At a glance
- Originator Polymun Scientific
- Class Adjuvants; AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I HIV-1 infections
Most Recent Events
- 22 Sep 2023 763SIP8/MPLA-5 is available for licensing as of 22 Sep 2023. https://www.polymun.com/about-us/
- 24 Jul 2023 Phase-I clinical trials in HIV-1 infections (Prevention) in Spain (IM) (NCT05772286)